[What is the REAL long-term risk of proton pump inhibitors?]

Autor: Ribiere S; Assistance publique Hôpitaux de Paris (AP-HP), hôpital Cochin, service de gastroentérologie, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Université Paris-Descartes, 12, rue de l'École de médecine, 75006 Paris, France., Guillaumot MA; Assistance publique Hôpitaux de Paris (AP-HP), hôpital Cochin, service de gastroentérologie, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Université Paris-Descartes, 12, rue de l'École de médecine, 75006 Paris, France., Barré A; Assistance publique Hôpitaux de Paris (AP-HP), hôpital Cochin, service de gastroentérologie, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Université Paris-Descartes, 12, rue de l'École de médecine, 75006 Paris, France., Abou Ali E; Assistance publique Hôpitaux de Paris (AP-HP), hôpital Cochin, service de gastroentérologie, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Université Paris-Descartes, 12, rue de l'École de médecine, 75006 Paris, France., Barret M; Assistance publique Hôpitaux de Paris (AP-HP), hôpital Cochin, service de gastroentérologie, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Université Paris-Descartes, 12, rue de l'École de médecine, 75006 Paris, France., Chaussade S; Assistance publique Hôpitaux de Paris (AP-HP), hôpital Cochin, service de gastroentérologie, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Université Paris-Descartes, 12, rue de l'École de médecine, 75006 Paris, France., Coriat R; Assistance publique Hôpitaux de Paris (AP-HP), hôpital Cochin, service de gastroentérologie, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France; Université Paris-Descartes, 12, rue de l'École de médecine, 75006 Paris, France. Electronic address: Romain.coriat@aphp.fr.
Jazyk: francouzština
Zdroj: Presse medicale (Paris, France : 1983) [Presse Med] 2019 May; Vol. 48 (5), pp. 503-510. Date of Electronic Publication: 2019 Mar 27.
DOI: 10.1016/j.lpm.2019.02.011
Abstrakt: Proton pump inhibitors (PPIs) are among the most prescribed drugs in the world. While their efficacy in acute management is indisputable, it has long been suggested that PPI therapy is safe in the long term. In recent years, there has been growing and justified concern about the long-term risks of PPIs. The majority of reported side effects are based on observational studies with a low level of evidence. Concerning digestive risks, PPIs seem to increase the risk of Salmonella and Campylobacter infections. However, the link between PPIs and Clostridium difficile infection is not established. Long-term PPIs may be responsible for an increased risk of gastric cancer according to several recent studies. With regard to extra-digestive risks, PPIs are associated with a moderate increase in the risk of chronic renal failure via an interstitial nephritis mechanism. PPIs also provide martial deficiency and may be associated with vitamin B12 and magnesium deficiency in some patients. Other adverse reactions have been suggested without any causal relationship being established (i.e., dementia or bone fractures, cardiovascular risk). In this review we will discuss the different long-term adverse effects of PPIs and their level of evidence.
(Copyright © 2019 Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: